Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-25

Clinical Trial Update: Efficacy and Safety of Atacicept in IgA Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 trial of atacicept in IgA nephropathy was terminated with posted results in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Atacicept (atacicept)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: IgA Nephropathy | Phase 2 | Status: TERMINATED | Results posted: 2021-02-25